Akari Therapeutics (AKTX) Stock Price, Quote, News & History | Benzinga

SPY766.87+0.47%QQQ718.89+1.28%BTC/USD—DIA517.79−0.25%GLD381.57−0.12%TLT79.87−0.23%

Akari Therapeutics PLC (AKTX) Stock Price, Quote, News & History

AKTXNASDAQ

Trade with Public

Trade with Public

$8.51

-0.33-3.73%

Last update: Oct 19, 8:01 AM

$9.14

0.303.39%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$8.51

Volume / Avg.

2.76K / 60.86K

Day Range

- - -

52 Wk Range

3.02 - 34.50

Market Cap

$20.89M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

1.15%

Days to Cover

1

Recent Akari Therapeutics PLC News

Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket

XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.

Avi Kapoor

Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy

Akari Therapeutics reports positive preclinical data for AKTX-101 in urothelial cancer, showing efficacy in models resistant to current ADCs.

Vandana Singh

Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pre-market trading while other stocks also saw gains/losses.

Avi Kapoor

VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other stocks also fall.

Avi Kapoor

Why Akari Therapeutics Stock Is Falling On Tuesday?

Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.

Kaustubh Bagalkote

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-10.76M

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

15.75M

Free Cash Flow (TTM)

-10.76M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

4.99M

Analyst Trends and Forecast

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$11.69M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.01

Earnings Yield % (TTM)

0.00%

Earnings Yield % (FWD)

-29.34%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$8.14

Company Debt

Total Debt

$693.00K

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$7.69M

Debt to Equity

0.04

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-$662.00K